Identification and characterization of small molecule antagonists of pRb inactivation by viral oncoproteins

Chemistry and Biology

Volumn 19, Issue 4, 2012, Pages 518-528

  Fera, Daniela ^a,b   Schultz, David C ^a   Hodawadekar, Santosh ^a   Reichman, Melvin ^c   Donover, Preston Scott ^c   Melvin, Jason ^b   Troutman, Scott ^a   Kissil, Joseph L ^a   Huryn, Donna M ^b   Marmorstein, Ronen ^a,b  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ONCOPROTEIN; RETINOBLASTOMA PROTEIN; STAUROSPORINE; THIADIAZOLIDINEDIONE INHIBITOR; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG IDENTIFICATION; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN MOTIF; VIRUS CELL INTERACTION; VIRUS INHIBITION; WART VIRUS;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; E2F TRANSCRIPTION FACTORS; G1 PHASE CELL CYCLE CHECKPOINTS; HELA CELLS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS E7 PROTEINS; RETINOBLASTOMA PROTEIN; SEQUENCE ALIGNMENT; THIADIAZOLES;

EID: 84860109082     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2012.03.007     Document Type: Article

References (48)

1. P.D. Adams, X.T. Li, W.R. Sellers, K.B. Baker, X.H. Leng, J.W. Harper, Y. Taya, and W.G. Kaelin Jr. Retinoblastoma protein contains a C-terminal motif that targets it for phosphorylation by cyclin-cdk complexes Mol. Cell. Biol. 19 1999 1068 1080
2. J.D. Baleja, J.J. Cherry, Z. Liu, H. Gao, M.C. Nicklaus, J.H. Voigt, J.J. Chen, and E.J. Androphy Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins Antiviral Res. 72 2006 49 59
3. E.R. Balog, J.R. Burke, G.L. Hura, and S.M. Rubin Crystal structure of the unliganded retinoblastoma protein pocket domain Proteins 79 2011 2010 2014
4. S.N. Boyer, D.E. Wazer, and V. Band E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway Cancer Res. 56 1996 4620 4624
5. E.M. Burd Human papillomavirus and cervical cancer Clin. Microbiol. Rev. 16 2003 1 17
6. K. Butz, C. Denk, A. Ullmann, M. Scheffner, and F. Hoppe-Seyler Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein Proc. Natl. Acad. Sci. USA 97 2000 6693 6697
7. C. Cordon-Cardo, J. Sheinfeld, and G. Dalbagni Genetic studies and molecular markers of bladder cancer Semin. Surg. Oncol. 13 1997 319 327
8. A. Dahiya, M.R. Gavin, R.X. Luo, and D.C. Dean Role of the LXCXE binding site in Rb function Mol. Cell. Biol. 20 2000 6799 6805
9. R.A. DeFilippis, E.C. Goodwin, L. Wu, and D. DiMaio Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells J. Virol. 77 2003 1551 1563
10. X. Dufour, A. Beby-Defaux, G. Agius, and J. Lacau St. Guily HPV and head and neck cancer Eur. Ann. Otorhinolaryngol. Head Neck Dis. 129 2012 26 31
11. A. Felsani, A.M. Mileo, and M.G. Paggi Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins Oncogene 25 2006 5277 5285
12. N. Ganguly, and S.P. Parihar Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis J. Biosci. 34 2009 113 123
13. M. Giarr, S. Caldeira, I. Malanchi, F. Ciccolini, M.J. Leão, and M. Tommasino Induction of pRb degradation by the human papillomavirus type 16 E7 protein is essential to efficiently overcome p16INK4a-imposed G1 cell cycle Arrest J. Virol. 75 2001 4705 4712
14. S.L. Gonzalez, M. Stremlau, X. He, J.R. Basile, and K. Münger Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7 J. Virol. 75 2001 7583 7591
15. N. Goudreau, D.R. Cameron, R. Déziel, B. Haché, A. Jakalian, E. Malenfant, J. Naud, W.W. Ogilvie, J. O'Meara, P.W. White, and C. Yoakim Optimization and determination of the absolute configuration of a series of potent inhibitors of human papillomavirus type-11 E1-E2 protein-protein interaction: a combined medicinal chemistry, NMR and computational chemistry approach Bioorg. Med. Chem. 15 2007 2690 2700
16. H. Griffin, R. Elston, D. Jackson, K. Ansell, M. Coleman, G. Winter, and J. Doorbar Inhibition of papillomavirus protein function in cervical cancer cells by intrabody targeting J. Mol. Biol. 355 2006 360 378
17. J.W. Harbour, and D.C. Dean The Rb/E2F pathway: expanding roles and emerging paradigms Genes Dev. 14 2000 2393 2409
18. J.W. Harbour, R.X. Luo, A. Dei Santi, A.A. Postigo, and D.C. Dean Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1 Cell 98 1999 859 869
19. D.M. Harper Currently approved prophylactic HPV vaccines Expert Rev. Vaccines 8 2009 1663 1679
20. C.H. Hensel, C.L. Hsieh, A.F. Gazdar, B.E. Johnson, A.Y. Sakaguchi, S.L. Naylor, W.H. Lee, and E.Y. Lee Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer Cancer Res. 50 1990 3067 3072
21. M. Jiang, and J. Milner Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference Oncogene 21 2002 6041 6048
22. F.D. Kitchin, and R.M. Ellsworth Pleiotropic effects of the gene for retinoblastoma J. Med. Genet. 11 1974 244 246
23. J.O. Lee, A.A. Russo, and N.P. Pavletich Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7 Nature 391 1998 859 865
24. X. Liu, and R. Marmorstein When viral oncoprotein meets tumor suppressor: a structural view Genes Dev. 20 2006 2332 2337
25. X. Liu, A. Clements, K.H. Zhao, and R. Marmorstein Structure of the human Papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor J. Biol. Chem. 281 2006 578 586
26. Y. Liu, Z. Liu, E. Androphy, J. Chen, and J.D. Baleja Design and characterization of helical peptides that inhibit the E6 protein of papillomavirus Biochemistry 43 2004 7421 7431
27. R. Luna-Medina, M. Cortes-Canteli, M. Alonso, A. Santos, A. Martínez, and A. Perez-Castillo Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation J. Biol. Chem. 280 2005 21453 21462
28. R. Luna-Medina, M. Cortes-Canteli, S. Sanchez-Galiano, J.A. Morales-Garcia, A. Martinez, A. Santos, and A. Perez-Castillo NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders J. Neurosci. 27 2007 5766 5776
29. A. Martinex TDZD: Selective GSK-3 inhibitors with great potential for Alzheimer disease Neurobiol. Aging 27 2006 S13-S13
30. A. Martinez, M. Alonso, A. Castro, C. Pérez, and F.J. Moreno First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease J. Med. Chem. 45 2002 1292 1299
31. A. Martinez, M. Alonso, A. Castro, I. Dorronsoro, J.L. Gelpí, F.J. Luque, C. Pérez, and F.J. Moreno SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors J. Med. Chem. 48 2005 7103 7112
32. M.E. McLaughlin-Drubin, and K. Münger Oncogenic activities of human papillomaviruses Virus Res. 143 2009 195 208
33. K. Münger, J.R. Basile, S. Duensing, A. Eichten, S.L. Gonzalez, M. Grace, and V.L. Zacny Biological activities and molecular targets of the human papillomavirus E7 oncoprotein Oncogene 20 2001 7888 7898
34. A.O. Rosa, M.P. Kaster, R.W. Binfaré, S. Morales, E. Martín-Aparicio, M.L. Navarro-Rico, A. Martinez, M. Medina, A.G. García, M.G. López, and A.L. Rodrigues Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice Prog. Neuropsychopharmacol. Biol. Psychiatry 32 2008 1549 1556
35. S.M. Rubin, A.L. Gall, N. Zheng, and N.P. Pavletich Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylation-induced E2F release Cell 123 2005 1093 1106
36. U.T. Rüegg, and G.M. Burgess Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases Trends Pharmacol. Sci. 10 1989 218 220
37. M. Scheffner, K. Münger, J.C. Byrne, and P.M. Howley The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines Proc. Natl. Acad. Sci. USA 88 1991 5523 5527
38. E.L. Schubert, M.F. Hansen, and L.C. Strong The retinoblastoma gene and its significance Ann. Med. 26 1994 177 184
39. N. Sima, W. Wang, D. Kong, D. Deng, Q. Xu, J. Zhou, G. Xu, L. Meng, Y. Lu, S. Wang, and D. Ma RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53 Apoptosis 13 2008 273 281
40. M. Singh, M. Krajewski, A. Mikolajka, and T.A. Holak Molecular determinants for the complex formation between the retinoblastoma protein and LXCXE sequences J. Biol. Chem. 280 2005 37868 37876
41. O. Stevaux, and N.J. Dyson A revised picture of the E2F transcriptional network and RB function Curr. Opin. Cell Biol. 14 2002 684 691
42. H.H. Sudhoff, H.P. Schwarze, D. Winder, L. Steinstraesser, M. Görner, M. Stanley, and P.K. Goon Evidence for a causal association for HPV in head and neck cancers Eur. Arch. Otorhinolaryngol. 268 2011 1541 1547
43. Y. Wang, R. Coulombe, D.R. Cameron, L. Thauvette, M.J. Massariol, L.M. Amon, D. Fink, S. Titolo, E. Welchner, and C. Yoakim Crystal structure of the E2 transactivation domain of human papillomavirus type 11 bound to a protein interaction inhibitor J. Biol. Chem. 279 2004 6976 6985
44. Q. Wei Pitx2a binds to human papillomavirus type 18 E6 protein and inhibits E6-mediated P53 degradation in HeLa cells J. Biol. Chem. 280 2005 37790 37797
45. P.W. White, A.M. Faucher, and N. Goudreau Small molecule inhibitors of the human papillomavirus E1-E2 interaction Curr. Top. Microbiol. Immunol. 348 2011 61 88
46. B. Xiao, J. Spencer, A. Clements, N. Ali-Khan, S. Mittnacht, C. Broceño, M. Burghammer, A. Perrakis, R. Marmorstein, and S.J. Gamblin Crystal structure of the retinoblastoma tumor suppressor protein bound to E2F and the molecular basis of its regulation Proc. Natl. Acad. Sci. USA 100 2003 2363 2368
47. C. Yee, I. Krishnan-Hewlett, C.C. Baker, R. Schlegel, and P.M. Howley Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines Am. J. Pathol. 119 1985 361 366
48. C. Yoakim, W.W. Ogilvie, N. Goudreau, J. Naud, B. Haché, J.A. O'Meara, M.G. Cordingley, J. Archambault, and P.W. White Discovery of the first series of inhibitors of human papillomavirus type 11: inhibition of the assembly of the E1-E2-Origin DNA complex Bioorg. Med. Chem. Lett. 13 2003 2539 2541